Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$65.54 USD

65.54
7,052,823

+0.76 (1.17%)

Updated May 6, 2024 04:00 PM ET

After-Market: $65.46 -0.08 (-0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ekta Bagri headshot

CAR T-Cell Therapies Under FDA Watch on Reports of Malignancies

by Ekta Bagri

The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.

GSK Key Drugs & Vaccines Help Stock Outperform Industry YTD

by Zacks Equity Research

Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates are expected drive the stock in the future quarters.

Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals

by Zacks Equity Research

Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals are part of the Zacks Industry Outlook article.

Ekta Bagri headshot

5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright

by Ekta Bagri

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.

Nalak Das headshot

Top 5 U.S. Giants for 2024 That Have Failed to Deliver in 2023

by Nalak Das

We have narrowed our search to five U.S. corporate giants that have failed to deliver in 2023. These are: PEP, PG, MMM, XOM, GILD.

The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics

by Zacks Equity Research

Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics are part of the Zacks top Analyst Blog.

Nalak Das headshot

5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024

by Nalak Das

We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.

Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead

by Zacks Equity Research

Arcellx (ACLX) and Gilead (GILD) expand their existing collaboration in cancer treatment. This deal is expected to close by year-end.

Ekta Bagri headshot

4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates

by Ekta Bagri

Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.

Gilead (GILD) Q3 Earnings Beat, Trodelvy Fuels Oncology Sales

by Zacks Equity Research

Gilead (GILD) reports better-than-expected results for the third quarter as Trodelvy boosts oncology sales and Biktarvy maintains momentum in the HIV franchise.

Compared to Estimates, Gilead (GILD) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Mark Vickery headshot

After-Hours Selling to Challenge Winning Streak Wednesday

by Mark Vickery

Gilead, eBay and Rivian all beat on the bottom line in Q3, but all three are selling the news.

Gilead Sciences (GILD) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Gilead (GILD) delivered earnings and revenue surprises of 19.90% and 4.08%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Markets Await Consumer Credit Report

by Zacks Equity Research

Markets Await Consumer Credit Report

Mark Vickery headshot

Can Markets Keep the Winning Streak Intact?

by Mark Vickery

Uber missed on headline although business was good, D.R. Horton beat and raised, and the U.S. trade deficit got slimmer.

Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More

by Zacks Equity Research

Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.

Earnings Preview: Illumina (ILMN) Q3 Earnings Expected to Decline

by Zacks Equity Research

Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $77.88 in the latest trading session, marking a +1.64% move from the prior day.

Gilead (GILD) Gears Up to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its third-quarter 2023 results.

Pfizer's (PFE) Key Drugs to Drive Q3 Earnings Amid COVID Decline?

by Zacks Equity Research

Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.

Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales

by Zacks Equity Research

Merck (MRK) beats Q3 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.

USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day.

Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider

by Zacks Equity Research

Gilead Sciences (GILD) concluded the recent trading session at $78.15, signifying a +0.76% move from its prior day's close.

Indrajit Bandyopadhyay headshot

3 Biotech Stocks With Decent Dividend for a Steady Return

by Indrajit Bandyopadhyay

Here we pick three medical device stocks, AbbVie (ABBV), Amgen (AMGN) and Gilead Sciences (GILD), which have a solid five-year dividend growth history.